Federal move to reschedule medical marijuana brings tax breaks, investment hopes

The Trump administration has handed the cannabis industry its most consequential federal tax break in years, even as marijuana remains illegal for recreational use nationwide. By moving state-licensed medical marijuana and FDA-approved marijuana products into Schedule III, the Justice Department stripped qualifying businesses of the punishing Section 280E burden that had blocked normal deductions for companies tied to Schedule I or II trafficking rules.

The order, issued April 23, marked a sharp practical shift for medical cannabis operators. Acting Attorney General Todd Blanche said the move covers FDA-approved drug products containing marijuana and medicinal marijuana products tied to qualifying state licenses, reflecting the long-standing role of state governments in regulating medical use. Treasury and the IRS said they expect significant positive tax consequences and plan to issue guidance on the federal tax issues created by the final order.

For the industry, the immediate payoff is arithmetic. Once 280E no longer applies, medical cannabis businesses can deduct ordinary expenses like rent, payroll and marketing, a change that could lift margins and improve valuations. That matters most for multistate operators with substantial medical exposure, especially companies that have spent years operating under compressed profits and weak access to capital.

Investors initially seized on the news, sending cannabis shares higher, but some of those gains faded as the narrow scope of the action became clearer. Adult-use marijuana remains Schedule I, and the federal change does not amount to nationwide legalization. Mixed operators that sell both medical and recreational products still face unresolved questions about how to allocate expenses, and market participants are still waiting for the Treasury and IRS to spell out how much relief will be available, and whether any of it will be retroactive.

The Justice Department’s action was paired with a separate notice restarting the formal administrative process to consider broader rescheduling. The Drug Enforcement Administration set a hearing to begin June 29, 2026, extending a process that began with a May 21, 2024 notice of proposed rulemaking. That proposal followed a 2023 recommendation from the Department of Health and Human Services to move marijuana to Schedule III, which in turn traced back to President Joseph R. Biden’s October 6, 2022 request for an expeditious review of marijuana scheduling.

The result is a policy-business contradiction with clear economic consequences. A conservative administration that ran on law-and-order politics is now helping unlock tax relief and investment potential for a sector long kept on the margins by federal prohibition. Whether this becomes a durable shift in federal cannabis policy or remains a politically convenient exception will depend on how far the broader rescheduling process goes, and how quickly regulators turn the new tax opening into workable rules.